Related Experiment Video
Updated: Mar 10, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Precision Medicine, Diabetes, and the U.S. Food and Drug Administration
1Department of Public Health Sciences and Virginia Center for Translational and Regulatory Sciences, University of Virginia School of Medicine, Charlottesville, VA rjm7cd@virginia.edu.
Abstract:
The U.S. Food and Drug Administration (FDA) has long sought to achieve the broader use of personalized medicine, which is better targeting of FDA-approved therapies through incorporating precise knowledge of a patient's underlying condition to therapies optimally chosen to match those needs. While some strides have been made in precision medicine-particularly in oncology and rare genetic diseases-most of the standard general medicine indications have yet to realize the benefits of precision-guided therapies. This includes those for diabetes mellitus (DM), both type 1 and type 2. Although the scientific and regulatory considerations needed to move to a more "precise" future of DM prevention and treatment differ between the two disease subsets, scientific advances in both must occur before the FDA can incorporate precision medicine into its oversight of DM drug development and approval. This article provides an overview of the regulatory expectations and challenges in realizing a future where the therapeutics for DM are informed by precise knowledge of a patient's genetics and specific phenotype.
More Related Videos
06:46A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacogenomics: Identification of New Drug Targets
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
Oral Hypoglycemic Agents: Biguanides and Glitazones